Found: 5
Select item for more details and to access through your institution.
Venetoclax in Combination with Azacitidine for the Treatment of Newly Diagnosed Acute Myeloid Leukemia: A Canadian Cost–Utility Analysis.
- Published in:
- Current Oncology, 2022, v. 29, n. 10, p. 7524, doi. 10.3390/curroncol29100592
- By:
- Publication type:
- Article
The Risk Reduction of Accidental Exposure-Related Systemic Allergic Reactions Extrapolated Based on Food Challenge Data After 1 Year of Peanut Oral Immunotherapy.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Use of risk-reducing surgeries in a prospective cohort of 1,499 BRCA1 and BRCA2 mutation carriers.
- Published in:
- Breast Cancer Research & Treatment, 2014, v. 148, n. 2, p. 397, doi. 10.1007/s10549-014-3134-0
- By:
- Publication type:
- Article
RE: Breast Cancer Risk After Salpingo-Oophorectomy in Healthy BRCA1/2 Mutation Carriers: Revisiting the Evidence for Risk Reduction.
- Published in:
- 2015
- By:
- Publication type:
- commentary
Cost-Effectiveness Analysis of Venetoclax in Combination with Azacitidine Versus Azacitidine Monotherapy in Patients with Acute Myeloid Leukemia Who are Ineligible for Intensive Chemotherapy: From a US Third Party Payer Perspective.
- Published in:
- PharmacoEconomics, 2022, v. 40, n. 8, p. 777, doi. 10.1007/s40273-022-01145-7
- By:
- Publication type:
- Article